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Background: Familial partial lipodystrophy of the Dunnigan type (FPLD2) presents with a decrease of subcu-
taneous adipose tissue (SAT) in the limbs and trunk. As thyroid hormones (TH) play an important role in
adipogenesis, we studied if SAT from subjects with FPLD2 have changes in the gene expression levels of
monocarboxylate transporter 8 (MCT8), a TH transporter, and TH nuclear receptors and in iodothyronine
deiodinases (DIOs) expression and activities that could affect TH bioavailability and action in white adipose
tissue.
Methods: Seven subjects with FPLD2 and 10 healthy controls were studied. Two biopsies of SAT were obtained
from each subject, one near the umbilicus and the other from the thigh. Expression of MCT8, DIO2, DIO3,
THRA1, THRB1, and RXRG mRNAs were quantified by real-time polymerase chain reaction. DIO1 and DIO2
activities in adipose tissue homogenates were determined. Serum thyroid-stimulating hormone and TH levels
were measured by chemiluminescence.
Results: Subjects with FPLD2 had lower levels of MCT8 mRNA expression in the thigh than in the abdomen
SAT, and lower than in the abdomen and thigh SAT from control subjects. FPLD2 subjects also had higher DIO2
expression and activity in the thigh than in the abdomen SAT and higher than in controls.
Conclusions: Thigh SAT from subjects with FPLD2 has lower expression of MCT8 and higher DIO2 expression
and activity than abdominal SAT, suggesting that changes in local TH metabolism may occur in areas with
lipoatrophy. DIO2 expression and activity in SAT suggest that DIO2 can regulate the metabolism and action of
TH in human white adipose tissue.
Introduction
Thyroid hormones (THs) regulate adipogenesis and adi-pose tissue lipogenesis and lipolysis (1). In vitro THs
induce an acceleration of adipocyte differentiation (2), and
several genes involved in the differentiation program of adi-
pocytes are regulated by triiodothyronine (T3) (1,3). THs also
upregulate gene expression and activity of lipogenic enzymes
inwhite adipose tissue (4,5), althoughT3-stimulated lipolysis is
higher than T3-stimulated lipogenesis (6). In hyperthyroidism,
lipolysis is enhanced in part because the adipose tissue has
an increased sensitivity to catecholamines that result from
an increased b-adrenoreceptor number and a decrease in
phosphodiesterase activity. Both regulations concur to increase
cAMP levels and hormone-sensitive lipase activity (7,8).
TH cell uptake is mediated by specific plasma membrane
transporters. Monocarboxylate transporter 8 (MCT8) is a TH-
specific transporter ubiquitously expressed. Mutations in
human MCT8 gene cause a syndrome with severe psycho-
motor retardation in affected males and a thyroidal pheno-
type in the affected subjects and the female carriers (9,10),
underlining the importance of MCT8 in cellular TH homeo-
stasis. MCT8 is expressed in human subcutaneous adipose
tissue (SAT), and although very little is known about its reg-
ulation, MCT8 expression in adipose tissue decreases during
septic shock (11).
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In humans, approximately 80% of T3 is produced by ex-
trathyroidal enzymatic deiodination of thyroxine (T4). SAT
expresses type 1 (DIO1), type 2 (DIO2), and type 3 (DIO3)
iodothyronine deiodinases, and DIO1 and DIO3 activities
have been reported in human SAT (11). These findings sug-
gest that iodothyronine deiodinases could play an important
role in regulating the concentration of T3 in the white adipose
tissue.
TH action depends on the tissue distribution and expres-
sion levels of thyroid hormone receptors (TRs), which are
ligand-regulated transcription factors that bind to thyroid
response elements (TREs) of target genes. TRs are encoded by
the THRA and THRB genes, which by alternative splicing give
rise to different TR isoforms (12). TRs bind to TREs predom-
inantly as heterodimers with the retinoid X receptor and to-
gether they also bind to other regulatory proteins that act as
corepressors and coactivators modulating TR transcription
function. All the isoforms of TRs are expressed in white adi-
pose tissue (11).
Familial partial lipodystrophy of the Dunnigan type
(FPLD2) is characterized by loss of SAT in the limbs and trunk
from puberty, accumulation of fat in the neck and face, and
predisposition to insulin resistance, leading to complications
such as glucose intolerance, dyslipidemia, high blood pres-
sure, liver steatosis, and increased risk of coronary heart dis-
ease. FPLD2 results from heterozygous missense mutations in
the LMNA gene (13), which codes for differently spliced
proteins, including lamin A, lamin C, and lamin AD10. Lamin
A is synthesized as a precursor, prelamin A (14), and subjects
with FPLD2 have an accumulation of prelamin A in SAT,
which is associatedwith a reduced expression of several genes
involved in adipocyte proliferation and differentiation (15).
Because of the important role of TH on adipocyte differen-
tiation and metabolism, we wondered if the peculiar adipose
tissue distribution of subjects with FPLD2 is associated with
changes in MCT8, DIO2, DIO3, THRA1, THRB1, and RXRG
mRNA expression levels andwith changes in DIO1 and DIO2
enzyme activities that could have an effect on TH bioavail-
ability and action in the white adipose tissue of these subjects.
Materials and Methods
Subjects
We have studied seven subjects with FPLD2 due to a mis-
sense mutation in LMNA gene (R482W), belonging to a pre-
viously published pedigree (16). Ten healthy participants
matched by age, sex, and body mass index were used as
controls. Anthropometrical, body composition, insulin resis-
tance status, and other relevant clinical data of the partici-
pants have been previously reported (15). This study was
approved by the ethics review panel of the Conselleria de
Sanidade (Xunta de Galicia, Spain) and performed according
to the ethical guidelines of the Declaration of Helsinki. Con-
trol and FPLD2 subjects gave informed consent for partici-
pation in the study and for publication of their clinical,
biochemical, and genetic information.
Serum analysis
Serum TH levels were measured by chemiluminescence
(ADVIA Centaur, Bayer Diagnostics, Barcelona, Spain) in
blood samples taken between 0800 and 0900 hours. Normal
reference values for serum thyroid-stimulating hormone
(TSH) were 0.41–4.94mU=L, for free T4 (FT4) 10.94–21.75 pM
(0.84–1.68 ng=dL), and for free T3 (FT3) 3.89–6.60 pM (2.52–
4.28 pg=mL).
Adipose tissue biopsies
Two biopsies of SAT, 1 cm each, were obtained from each
participant under sterile conditions and local anesthesia. One
biopsy was taken from subcutaneous deposits 4 cm lateral to
the umbilicus and the other from subcutaneous deposits in the
lateral side of the thigh. Fat samples were cleaned of visible
fibrous connective tissue and blood vessels and were divided
into roughly equal portions, one of them was snap-frozen
immediately in liquid nitrogen and stored at 808C until
further analysis.
RNA isolation and real-time polymerase chain reaction
Total RNA was extracted from the subcutaneous biopsies
using a commercial kit (RNeasy Lipid Tissue Kit; Qiagen,
Madrid, Spain) following the manufacturer’s instructions.
RNA was reverse transcribed using M-MLV reverse tran-
scriptase (Invitrogen, Barcelona, Spain), 1mg total RNA, 5mM
random hexamers, and 2mM deoxynucleotides (Ecogen,
Barcelona, Spain) in a 20 mL reaction volume.
Expression of MCT8, DIO2, DIO3, THRA1, THRB1, and
RXRG mRNAs and the internal control RNA polymerase II
was quantified in a thermal cycler (Light Cycler 2.0; Roche
Diagnostics, Sant Cugat del Valles, Spain) using specific probes
and oligonucleotide primers (Universal ProbeLibrary; Roche
Diagnostics). Real-time polymerase chain reaction conditions
are available upon request. Results were normalized to the
RNA polymerase II gene, using the 2DDCt method (17).
Determination of DIO1 and DIO2 activities
DIO1 and DIO2 activities were assayed in adipose tissue
homogenates prepared (1:8, weight=volume) in 0.32M su-
crose, 10mM HEPES, and 2mM dithiothritol (DTT). Because
of difficulties during pipetting, the homogenates were
centrifuged for 5 minutes at 1000 rpm to separate the lipid
cake as upper phase and the infranatant was used for the
deiodinase assays. The protein content was 20–50 mg pro-
tein=50mL homogenate used in the assay. Each adipose tissue
sample was assayed in duplicates.
For the determination of DIO1 activity, [125I]-rT3
(70,000 cpm=tube), 100 nM rT3, and 2mM DTT were incu-
bated at 378C for 1 hour, using 20–40 mg protein=100mL
reaction mixture (18). Results are expressed in pmol per
min=mg protein for DIO1 activity.
DIO2 activity was assayed using [125I]-T4
(60,000 cpm=tube), 2 nM T4þ 1mM T3 (to inhibit D3 activity),
20mMDTT, and 1mMPTU for 1 hour at 378C, using the same
protein as above for DIO1 (19). Results are expressed in fmol
per h=mg protein for DIO2 activity.
Before each assay, [125I]-rT3 or [125I]-T4 was purified by
paper electrophoresis to separate the contaminating iodide.
The [125I] released was separated by ion-exchange chroma-
tography on Dowex-50W-X2 columns equilibrated in 10%
acetic acid. The protein content was determined by the
method of Lowry et al. (20), after precipitation of the
homogenates with 10% trichloroethane (TCA) to avoid
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interferences from DTT in the colorimetric reaction. The val-
ues shown are the mean of 6–10 adipose samples.
Data analysis
Gene expression levels and enzyme activity are shown as
median and interquartile range. Serum hormone levels are
shown as mean standard deviation. Unpaired t-test was
used to evaluate for differences between the two groups in
TSH and THs serum levels. One-way analysis of variance
followed by the Tukey–Kramer test for multiple comparisons
was used to evaluate differences in gene expression and
deiodinases activities. Data analyses were performed with
GraphPad Prism 5.00 (GraphPad Software, La Jolla, CA).
Results
No statistically significant differences were observed be-
tween control and FPLD2 subjects in serum levels of TSH
(1.61 0.91mU=L control vs. 1.56 0.33mU=L FPLD2, ns),
FT4 (14.83 1.93 pM [1.15 0.15 ng=dL] control vs.
12.15 2.52 pM [1.13 0.19 ng=dL] FPLD2, ns), and FT3
(4.79 0.38 pM [3.11 0.24 pg=mL] control vs. 5.00 0.5 pM
[3.25 0.35 pg=mL] FPLD2, ns) and in FT3=FT4 index
(0.32 0.05 control vs. 0.35 0.07 FPLD2, ns).
Subjects with FPLD2 had lower MCT8 and higher DIO2
relative mRNA expression in the thigh than in the abdominal
SAT. Thigh SAT from FPLD2 subjects had lower MCT8 and
higher DIO2 mRNA expression than thigh and abdominal
SAT from controls (Fig. 1A, E). No differences in relative
mRNA expression of THRA1, THRB1, RXRG, and DIO3were
observed between and within groups (Fig. 1B–F).
DIO1 activity was detected in all SAT samples. Although
DIO1 activity tended to be higher in thigh adipose tissue from
subjects with FPLD2, no statistically significant differences
were achieved (Fig. 2A).
DIO2 activity in thigh SAT was higher than in abdominal
SAT in FPLD2 and also higher than in thigh and abdomen
SAT from controls (Fig. 2B).
Discussion
Subjects with FPLD2 lose adipose tissue in limbs and but-
tocks and accumulate fat in the face and neck. In our clinical
experience, however, when these patients become obese they
also accumulate subcutaneous fat in the abdomen. To date,
FIG. 1. MCT8, THRA1, THRB1, RXRG, DIO2, and DIO3 mRNA expressions were normalized to RNA polymerase II gene.
Abdominal gene expression in control subjects was chosen arbitrarily as the reference value and relative mRNA expression in
SAT from thigh of controls and from thigh and abdomen of FPLD2 subjects were calculated against it. One-way analysis of
variance followed by the Tukey–Kramer test for multiple comparisons were used for statistical analysis. The thigh SAT from
subjects with FPLD2 had the lowest relative mRNA MCT8 expression (A) and the highest relative mRNA DIO2 expression
(E). No differences in relative MCT8 and DIO2 gene expression were observed between abdominal SAT from FPLD2 subjects
and thigh and abdominal SAT from controls. No statistically significant differences between or within groups were observed
in regional SAT relative expression for THRA1 (B), THRB1 (C), RXRG (D), and DIO3 (F). Values are shown as median and
interquartile range. *p< 0.05 between FPLD2 thigh SAT versus FPLD2 abdomen and controls’ thigh and abdomen SAT.
FPLD2, familial partial lipodystrophy of the Dunnigan type; C, controls; SAT, subcutaneous adipose tissue; MCT8, mono-
carboxylate transporter 8.
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the cause of these regional differences has not been identi-
fied, but intrinsic differences in the properties of fat cells
from specific anatomical deposits could be implicated. Ac-
cordingly, we showed recently (15) that, in patients with
FPLD2, loss of SAT is associated with a reduced expres-
sion of several genes involved in adipocyte proliferation=
differentiation and this was found both in genes related to
the cellular cycle (protein Rb gene [RB1], cyclin D1 gene
[CCND1], and cyclin D3 gene [CCND3]) and in genes in-
volved in adipocyte differentiation (peroxisome proliferator-
activated receptor gamma gene [PPARG2], lipoprotein lipase
gene [LPL], and glucose transporter 4 [GLUT4]). Also,
we have previously reported that abdomen and thigh SAT
of control subjects have different levels of expression of
CCND3, CCND1, and PPARG2 genes, but its significance
remains unknown.
According to our previous observations, we have now
found regional changes in SAT expression levels of TH
transporter MCT8 and DIO2 and in DIO2 activity between
controls and FPLD2 subjects. These findings suggest that TH
bioavailability and actions in adipose tissue could be different
in FPLD2 versus control subjects.
Subjects with FPLD2 have lowerMCT8 expression levels in
thigh than in abdomen SAT samples, with no differences
observed in THRB1, THRA1, and RXRG mRNA expression.
Although TH levels in tissue samples were not measured
because of the little amount of adipose tissue available for this
study, MCT8 gene is highly expressed in SAT (11) and a de-
crease inMCT8 expression might reduce the TH uptake in the
adipocytes; these results suggest that the loss of adipose tissue
observed in the thigh of subjects with FPLD2 could be asso-
ciated to lower supply of TH preventing further lipolysis in
the already scarce SAT. The loss of adipose tissue in lamino-
pathies and lipodystrophies are related to a reduced differ-
entiation of mesenchymal stem cells along the adipogenic
lineage (21); THs act as pleiotropic factors in many tissues
during development, by regulating genes involved in differ-
entiation, including adipogenesis (1), and a decrease in
TH supply into the thigh mesenchymal stem cells and
preadipocytes could be also related to a reduced differentia-
tion and proliferation of the adipogenic lineage.
DIO2mRNA expression and activity were detected in SAT
samples, with the highest levels found in the thigh SAT from
FPLD2 subjects. DIO2 regulates the concentration of active
TH within cells from different tissues (22) and more than half
of T3 inside some tissues can be generated locally under DIO2
activity (23). DIO2 is essential as a local source of T3 in brown
adipose tissue (BAT) to facilitate adaptive thermogenesis
under cold exposure (24,25). Also bile acids can confer resis-
tance to diet-induced obesity in mice via upregulation ofDio2
expression in BAT (26). These findings indicate that, at least in
rodents, Dio2 has a central role not only in cold-induced
thermogenesis but also in adipose tissue metabolism (27).
However, adult humans under thermoneutral conditions (28–
30) do not have substantial amounts of BAT and the role of
DIO2 in white adipose tissue metabolism remains unknown.
In rats, Dio2 mRNA expression is present in white adipose
tissue (31), and Ucp1 knockout mice are lean and have in-
creased expression of Dio2 in white adipose tissue (32). In a
previous human study, we reported mRNA expression of
DIO2 but no enzyme activity in white adipose tissue (11). In
this study, DIO2 mRNA expression was detected and we
provided evidences that DIO2mRNA expression is regulated
because SAT from thigh of FPLD2 subjects showed higher
levels of expression than the other studied SAT depot, and
finally higher DIO2 gene expression levels were associated
with higher levels of enzyme activity. The differences in DIO2
activity between this study and our previous study remain
unknown but could be related in part to different methodo-
logies to measure the enzyme activity.
The significance of a higher activity of DIO2 in SAT from the
thigh of subjects with FPLD2 versus their abdominal SAT and
versus both thigh and abdominal SAT from controls remains
unknown. If the decrease in fat TH transporter MCT8 mRNA
expression is related to a lower uptake of TH for the adipocyte,
then an increase in DIO2 expression and activity seems an
adaptive response to prevent intracellular hypothyroidism.
On the contrary, if the increase in DIO2 activity is a primary
FIG. 2. Type 1 (DIO1) (A) and type 2 (DIO2) (B) iodothyronine deiodinase activities were determined in abdominal and
thigh SAT from control and FPLD2 subjects. One-way analysis of variance followed by the Tukey–Kramer test for multiple
comparisons was used for statistical analysis. DIO2 activity was significantly higher in thigh SAT of FPLD2 subjects than in
their abdominal SAT and than in controls’ abdominal and thigh SAT. No differences were observed in DIO1 activity. Values
are shown as median and interquartile range. *p< 0.05 between FPLD2 thigh SAT versus FPLD2 abdomen and controls’ thigh
and abdomen SAT.
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molecular mechanism occurring in the adipocytes from the
thigh of FPLD2 subjects, such mechanism would create a sit-
uation of local hyperthyroidism and a decrease in TH trans-
porters would limit the uptake of THs and lipolysis. THs
increase LPL and GLUT4 genes expression and decrease the
expression of sterol regulatory element binding transcription
factor 1 (SREBP-1c) (1,3). We have previously reported that
LPL and GLUT4 mRNA expression were reduced and that
SREBP-1cmRNAexpression did not change in thigh SAT from
FPLD2 subjects (15), an argument against the hypothesis of
hyperthyroidism in thigh SAT of these subjects. DIO1 and
DIO3 mRNA expression and activities are stimulated by T3
and no increase in DIO1 activity and DIO3 expression were
observed in the thigh SAT of subjects with FPLD2 (22).
Adipocyte precursor cells give rise to white and brown
adipocytes and the retinoblastoma protein regulates white
versus brown adipocyte differentiation (33) with functional
inactivation of retinoblastoma protein causing the transdif-
ferentiation of white into brown adipocytes. The loss of SAT
in our patients with FPLD2 is related to a decrease inRB1 gene
expression (15) and to an increase in PREF1 gene expression, a
gene highly expressed in preadipocytes but not in mature
adipocytes. The higher DIO2 activity in the thigh adipose
tissue from FPLD2 patients could be related to a transdiffer-
entiation of white adipocytes into brown adipocytes that have
a high DIO2 activity. UCP1 is a marker of BAT and UCP1
mRNAexpressionwas not detected in SAT fromboth controls
and subjects with FPLD2 (data not shown), suggesting that
the studied SAT samples were white adipocytes.
Conclusion
SAT from subjects with FPLD2 have regional differences in
the expression levels of TH transporter MCT8 and DIO2 and
in DIO2 activity. The thigh from subjects with FPLD2, a body
area with significant loss of fat, has lower expression ofMCT8
and higher DIO2 expression and activity than abdominal fat,
suggesting that changes in local TH availability occur in those
areas with lipoatrophy. A significant DIO2 expression and
activityweremeasured in SAT fromhumans, and although its
physiological role remains unknown, it indicates that DIO2
could regulate T3 availability having an important role in
human white adipose metabolism.
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